{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:12:44Z","timestamp":1758816764586},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","surgpath.theclinics.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.path.2016.01.009","type":"journal-article","created":{"date-parts":[[2016,4,11]],"date-time":"2016-04-11T22:26:36Z","timestamp":1460413596000},"page":"301-306","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Testing for Hereditary Predisposition in Patients with Gynecologic Cancers, Quo Vadis?"],"prefix":"10.1016","volume":"9","author":[{"given":"Gillian","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasmintan A.","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5182","key":"10.1016\/j.path.2016.01.009_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A\u00a0strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.path.2016.01.009_bib2","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1126\/science.8091231","article-title":"Localisation of a breast cancer susceptibility gene (BRCA2) to chromosome 13q by genetic linkage analysis","volume":"265","author":"Wooster","year":"1994","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.path.2016.01.009_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc3878","article-title":"Milestones of Lynch syndrome: 1895-2015","volume":"15","author":"Lynch","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.path.2016.01.009_bib4","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1038\/ncomms4156","article-title":"Integrated analysis of germline and somatic variants in ovarian cancer","volume":"5","author":"Kanchi","year":"2014","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.path.2016.01.009_bib5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ygyno.2015.02.017","article-title":"Two decades beyond BRCA1\/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy","volume":"137","author":"Walsh","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.path.2016.01.009_bib6","first-page":"151","article-title":"The protein truncation test in mutation detection and molecular diagnosis","volume":"375","author":"Hauss","year":"2007","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.path.2016.01.009_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0027-5107(93)90060-S","article-title":"Current methods of mutation detection","volume":"285","author":"Cotton","year":"1993","journal-title":"Mutat Res"},{"issue":"5","key":"10.1016\/j.path.2016.01.009_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00125817-200109000-00002","article-title":"Screening for mutations in a genetically heterogeneous disorder: DHPLC versus DNA sequence for mutation detection in multiple genes causing Charcot-Marie-Tooth neuropathy","volume":"3","author":"Takashima","year":"2001","journal-title":"Genet Med"},{"issue":"12","key":"10.1016\/j.path.2016.01.009_bib9","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","article-title":"DNA sequencing with chain-terminating inhibitors","volume":"74","author":"Sanger","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.path.2016.01.009_bib10","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bjc.6602121","article-title":"Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification","volume":"91","author":"Bunyan","year":"2004","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.path.2016.01.009_bib11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ajhg.2009.06.022","article-title":"Massively parallel sequencing: the next big thing in genetic medicine","volume":"85","author":"Tucker","year":"2009","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.path.2016.01.009_bib12","doi-asserted-by":"crossref","first-page":"9.15.1","DOI":"10.1002\/0471142905.hg0915s81","article-title":"Genetic tests: clinical validity and clinical utility","volume":"81","author":"Burke","year":"2014","journal-title":"Curr Protoc Hum Genet"},{"issue":"23","key":"10.1016\/j.path.2016.01.009_bib13","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"44","key":"10.1016\/j.path.2016.01.009_bib14","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1016\/j.path.2016.01.009_bib15","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1200\/JCO.2013.53.6607","article-title":"Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment","volume":"32","author":"Kurian","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.path.2016.01.009_bib16","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/annonc\/mdv278","article-title":"BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance","volume":"26","author":"Eccles","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.path.2016.01.009_bib17","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1200\/JCO.2013.50.0272","article-title":"Genome sequencing of multiple primary tumors reveals a novel PALB2 variant","volume":"34","author":"Schrader","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.path.2016.01.009_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13073-014-0069-3","article-title":"Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients","volume":"6","author":"Scollon","year":"2014","journal-title":"Genome Med"},{"issue":"8","key":"10.1016\/j.path.2016.01.009_bib19","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.path.2016.01.009_bib20","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.path.2016.01.009_bib21","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.drudis.2015.08.005","article-title":"Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials","volume":"20","author":"Hyman","year":"2015","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.path.2016.01.009_bib22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1001\/jamaoncol.2015.5208","article-title":"Germline variants in targeted tumor sequencing using matched normal DNA","volume":"2","author":"Schrader","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.path.2016.01.009_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/jnci\/94.1.61","article-title":"Frequency of BRCA1 dysfunction in ovarian cancer","volume":"94","author":"Geisler","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.path.2016.01.009_bib24","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/94.18.1396","article-title":"Inactivation of BRCA1 and BRCA2 in ovarian cancer","volume":"94","author":"Hilton","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"283","key":"10.1016\/j.path.2016.01.009_bib25","doi-asserted-by":"crossref","first-page":"283ra53","DOI":"10.1126\/scitranslmed.aaa7161","article-title":"Personalized genomic analyses for cancer mutation discovery and interpretation","volume":"7","author":"Jones","year":"2015","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.path.2016.01.009_bib26","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaoncol.2015.3048","article-title":"Utilization and outcomes of BRCA genetic testing and counseling in a national commercially insured population: The ABOUT Study","volume":"1","author":"Armstrong","year":"2015","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.path.2016.01.009_bib27","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1055-9965.EPI-03-0545","article-title":"Utilization of BRCA1\/BRCA2 mutation testing in newly diagnosed breast cancer patients","volume":"14","author":"Schwartz","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"10.1016\/j.path.2016.01.009_bib28","doi-asserted-by":"crossref","first-page":"646","DOI":"10.5694\/mja13.11218","article-title":"The Angelina Jolie effect","volume":"199","author":"James","year":"2013","journal-title":"Med J Aust"},{"issue":"5","key":"10.1016\/j.path.2016.01.009_bib29","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s13058-014-0442-6","article-title":"The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services","volume":"16","author":"Evans","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.path.2016.01.009_bib30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13073-015-0128-4","article-title":"Development of cancer genetic services in the UK: A national consultation","volume":"7","author":"Slade","year":"2015","journal-title":"Genome Med"},{"issue":"4","key":"10.1016\/j.path.2016.01.009_bib31","doi-asserted-by":"crossref","first-page":"436","DOI":"10.7861\/clinmedicine.14-4-436","article-title":"Mainstreaming genetic testing of cancer predisposition genes","volume":"14","author":"Rahman","year":"2014","journal-title":"Clin Med"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918116000210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918116000210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T12:26:51Z","timestamp":1536841611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875918116000210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1875918116000210"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2016.01.009","relation":{},"ISSN":["1875-9181"],"issn-type":[{"value":"1875-9181","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Testing for Hereditary Predisposition in Patients with Gynecologic Cancers, Quo Vadis?","name":"articletitle","label":"Article Title"},{"value":"Surgical Pathology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.path.2016.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}